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ORIGINAL ARTICLE
Introductions: Although randomized clinical trials showed no 
benefit from combining epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs) with standard chemotherapy for 
advanced non–small-cell lung cancer (NSCLC), better results might 
be obtained by combining EGFR-TKI with individual agents that are 
substrates for the adenosine triphosphate binding cassette transport-
ers (ABCTs) because EGFR-TKIs can inhibit their efflux. The com-
bination effects deserved to be further examined in vitro.
Methods: The combination effects of gefitinib with three antimi-
crotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or 
with gemcitabine were tested in 17 NSCLC cell lines using the tetra-
zolium colorimetric assay and classical isobole method. The effects 
of drug combinations, identified by the values of mean combination 
index (mCIs), were correlated with the expression levels of ABCTs. 
Dose-versus-log-response curves were analyzed to further evaluate 
the possible mechanisms of drug interactions.
Results: Synergistic gefitinib/AMTA interactions were observed in 
the tested cell lines. The synergism was more robust in the four lines 
overexpressing de novo or acquired P-glycoprotein (Pgp; individual 
mCIs range, 0.484–0.859; all p values were < 0.05), or in 12 cell 
lines exhibiting no sensitizing EGFR mutations (group mCIs for 
gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/vinorelbine 
were 0.869, 0.82, and 0.853, respectively. All p values were < 0.02). 
The synergism could be observed in cells expressing nearly undetect-
able Pgp and other ABCTs tested in this study. The combination of 
gefitinib/gemcitabine was additive (mCI = 1.027).
Conclusions: Combined gefitinib/AMTAs showed synergism in 
NSCLC cells harboring no sensitizing EGFR mutations. Gefitinib 
could enhance AMTA effects through mechanisms not restricted to 
Pgp blockage.
Key Words: Gefitinib, Antimicrotubule agent, P-glycoprotein, Syner-
gism, Non–small-cell lung cancer.
(J Thorac Oncol. 2012;7: 1218–1227)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been documented as an effective 
targeted therapy for non–small-cell lung cancer (NSCLC).1 
Four large-scale randomized trials were conducted to explore 
the role of EGFR-TKIs in combination with standard frontline 
chemotherapy.2–5 Unexpectedly, none demonstrated a favor-
able outcome. Previous preclinical studies suggested that G1 
cell-cycle arrest induced by EGFR-TKI could interfere with 
the G2/M toxicity of chemotherapeutics, thus leading to antag-
onism in EGFR wild-type NSCLC cells.6 This cell-cycle– 
specific antagonism is an explanation for the study failures.
In contrast, sensitizing EGFR mutant cells undergo apop-
tosis in response to EGFR-TKIs. This might further potentiate 
the apoptotic effects of chemotherapeutic agents, thereby enhanc-
ing cell death.6 Clinically, exploratory molecular analysis in the 
Tarceva Responses in Conjunction with Paclitaxel and Carboplatin 
(TRIBUTE) study7 showed that patients with EGFR-mutant 
tumors had a higher response rate to frontline chemotherapy with 
erlotinib than without erlotinib. Therefore, it has been presumed 
that tumors with sensitizing EGFR mutations are more likely to 
show synergism between EGFR-TKIs and chemotherapeutics.
More recently, the Cancer and Leukemia Group B 
30406 study8 showed that sensitizing EGFR mutations iden-
tify patients more likely to benefit from single erlotinib and 
erlotinib plus paclitaxel/carboplatin in a never- or light-smok-
ing population. However, the similar efficacy of single and 
combination regimens argues against the speculation about a 
synergism existing between EGFR-TKI and chemotherapeu-
tics in EGFR-mutant cells.
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We have demonstrated that in most EGFR wild-type 
and sensitizing-mutant NSCLC cell lines the concomitant 
gefitinib/cisplatin showed obvious antagonism.9 The EGFR-
TKI/platinum antagonism is a possible reason for the failure of 
those randomized trials.2–5,8 Our in vitro findings concur with 
the results of the Cancer and Leukemia Group B 30406 trial 
and suggest that the concomitant combination of platinum-
based regimen with EGFR-TKI is not a good strategy for 
improving outcome of advanced NSCLC, including tumors 
harboring sensitizing EGFR mutations. Moreover, Hirsch et 
al.10 tested the strategy of pharmacodynamic separation that 
was originally developed to avoid assumed cell-cycle–specific 
antagonist in EGFR wild-type cells by using intercalated 
therapy for advanced NSCLC. However, the results failed to 
support combined erlotinib and platinum-based chemotherapy 
in frontline treatment of EGFR-selected patients.
EGFR-TKIs have been shown to exhibit an off-target 
blocking effect on adenosine triphosphate binding cassette 
transporters (ABCTs), including the multiple-drug resistance 
(MDR)1-encoded P-glycoprotein (Pgp) and breast cancer 
resistance protein (BCRP).11–14 Initial exposure to drugs that 
are ABCT substrates can trigger ABCT-associated efflux and 
decrease intracellular drug accumulation, subsequently lead-
ing to MDR and treatment failure.11 These drugs include 
antimicrotubule agents (AMTAs) commonly used in NSCLC 
treatment, namely paclitaxel, docetaxel, and vinorelbine. 
Because these agents are substrates of Pgp and multidrug 
resistance-associated proteins (MRP, another member of the 
ABCT family) but not BCRP,15–18 it is reasonable to expect 
that EGFR-TKIs would enhance AMTA effects in cancer cells 
bearing Pgp, either de novo or acquired, regardless of their 
EGFR-mutation status.
We therefore hypothesized that synergisms might be 
obtained by combining EGFR-TKI with individual agents 
that are substrates of the ABCTs because EGFR-TKIs can 
inhibit their efflux. In this study, by examining 15 unselected 
NSCLC cell lines expressing wild-type or mutant EGFR and 
two doxorubicin-induced Pgp-overexpressing subclones, we 
evaluated the combination effects of gefitinib, an EGFR-TKI, 
with four commonly used chemotherapeutic agents at the 
cellular level. In particular, we focused on whether the com-
bination effect was different between cells with and without 
sensitizing EGFR mutations.
MATERIALS AND METHODS
Cell Lines and Culture
A total of 17 NSCLC cell lines were tested (Table 1). 
Fifteen cell lines were established and characterized from 
tumors of previously untreated patients, including eight 
adenocarcinomas, three adenosquamous-cell carcinomas, one 
squamous-cell carcinoma, and three large-cell carcinomas.19 
Four cell lines demonstrated EGFR gene mutations: line 
H3255 at exon 21, L858R; line HCC827 at exon 19, del 
E746-A750; line PC-9 at exon 19, del E746-A750; and line 
H820 at exon 19, del E746-E749, and exon 20, T790M. Line 
H820 also showed c-Met amplification.20,21 The other two cell 
lines, H23-A0.1 and H23-A0.3, were obtained from long-term 
cultures of NCI-H23 cells in RPMI-1640 supplemented with 
5% heat-inactivated fetal bovine serum (R5) containing 0.1 
and 0.3 μM doxorubicin, respectively. All the lines were 
maintained in R5 for at least 3 months before testing and 
recently genotyped.9
Expression Levels of MDR-Associated 
Transcripts
The levels of MDR-associated genes (MDR1, BCRP, 
MRP1, and MRP2) were determined using real-time quantita-
tive reverse transcription polymerase chain reaction (qRT-PCR) 
with the Chromo4 Four-Color Real-Time System (Bio-Rad 
Laboratories, Hercules, CA). Total RNA (5 μg) extracted from 
cells with the use of Tri-Reagent (Sigma-Aldrich, St. Louis, 
MO) was subjected to reverse transcription using the ImProm-
II Reverse Transcription System (Promega, Madison, WI). 
The resulting cDNA was then subjected to qRT-PCR analysis 
with a DyNamo Flash SYBR Green qPCR Kit (Finnzymes, 
Espoo, Finland). The forward and reverse primers were 5′ TCC 
TGG AGC GGT TCT ACG 3′ and 5′ ATA GGC AAT GTT 
CTC AGC AAT G 3′ for MDR1 (GenBank accession number 
NM_000927); 5′ CCG TGG TGT GTC TGG AGG AG 3′ and 
5′ CGA GGC TGA TGA ATG GAG AAG ATG 3′ for BCRP 
(GenBank accession number AF_09895); 5′ GCT GAT GGA 
GGC TGA CAA G 3′ and 5′ GCT GAG GAA GGA GAT GAA 
GAG 3′ for MRP1 (GenBank accession number L_05628); 
and 5′ TTA TTC ACT GCG GCT CTC ATT C 3′ and 5′ CAT 
CCA CAG ACA TCA GGT TCA C 3′ for MRP2 (GenBank 
accession number NM_000392), respectively. Glyceraldehyde-
3-phosphate dehydrogenase messenger RNA was used as an 
internal standard (reference). The forward and reverse primers 
were 5′-GAG TCC ACT GGC GTC TTC 3′ and 5′ GAT GAT 
CTT GAG GCT GTT GTC 3′ (GenBank accession number 
M_33197), respectively. MDR-associated gene levels were nor-
malized to glyceraldehyde-3-phosphate dehydrogenase (ΔCt). 
The relative expression levels were calculated using the equa-
tion 2−ΔΔCt as the values relative to that of the calibrator sample, 
NCI-H23.22 Three assays were performed independently.
Functional Assay of ABCT(Pgp)-Mediated Drug 
Efflux
Rhodamine 6G (Alexis Biochemicals, Lausen, 
Switzerland), a substrate of Pgp, was used as a fluorescent probe 
to evaluate the function of ABCTs. NCI-H23, H23-A0.1, and 
H23-A0.3 cells were seeded in 96-well microtiter plates in qua-
druplicate wells for each treatment. After culturing overnight, 
the cells were pretreated with gefitinib (Iressa; AstraZeneca 
Pharmaceuticals, Wilmington, DE) at a concentration of 0 (con-
trol), 0.32, 1, 3.2, or 10 μM, or with 5 μM reserpine (Sigma-
Aldrich, St. Louis, MO), a Pgp inhibitor, for 90 minutes. After 
washing twice with 200 μl of fresh medium followed by incu-
bation with 0.3 μM rhodamine 6G for 15 minutes, micrographs 
were taken using a reverse fluorescence microscope.
In Vitro Drug Testing
We tested the cytotoxicities of gefitinib, a small mol-
ecule EGFR-TKI, which interrupts signaling through the 
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mutated EGFR in target cells, and four commonly used 
chemotherapeutic agents, including gemcitabine (Gemzar; 
Eli Lilly, Indianapolis, IN), paclitaxel (Taxol; Bristol-
Myers Squibb, Princeton, NJ), docetaxel (Taxotere; Sanofi-
aventis, Bridgewater, NJ), and vinorelbine (Navelbine; 
GlaxoSmithKline, Philadelphia, PA). Gemcitabine is a nucle-
oside analog. The triphosphate analog of gemcitabine replaces 
cytidine during DNA replication. The process arrests tumor 
growth, resulting in apoptosis. Paclitaxel and docetaxel pro-
hibit cell growth by stabilizing microtubules within the cell. 
Vinorelbine interferes with microtubule assembly to inhibit 
mitosis at metaphase during cell division. Among these 
agents, paclitaxel, docetaxel, and vinorelbine are AMTAs.
Study Design and Drug Combinations
In vitro drug combination testing was performed 
using the tetrazolium dye (3-[4,5-dimethyl-2-thiazolyl]-2,5- 
diphenyl-2H-tetrazolium bromide) colorimetric assay, designed 
and performed as we described in detail previously.9,23–25 We 
used the classical isobole method9,26,27 to determine the in vitro 
TABLE 1. Cell-Line Characteristics
Cell 
Linea
Relative Expression Levels of the ABCT-Related Genes
MRP2
EGFR 
Mutation20,21
Gefitinibc  
IC
50
, μM
Cell 
typeb MDR1 (Pgp) BCRP MRP1
Cell lines established from previously untreated patients (N = 15)
1. H23 A 1.0 1.0 1.0 1.0 Wild 10.676  
(10.298, 11.053)
2. H125 AS 24.6  
(18.9, 30.4)
2.1  
(1.7, 2.4)
37.8  
(36.3, 39.4)
749.6  
(724.4, 744.8)
Wild 15.822  
(15.667, 15.977)
3. H226 S 1.2  
(0.2, 0.3)
0.3  
(0.2, 0.4)
10.0  
(7.0, 13.1)
1.6  
(1.4, 1.9)
Wild 8.990  
(7.651, 10.329)
4. H322 BAC 0.2  
(0.2, 0.3)
0.6  
(0.5, 0.8)
46.5  
(42.5, 50.5)
873.1  
(757.7, 988.5)
Wild 0.269  
(0.160, 0.377)
5. H358 BAC 0.7  
(0.5, 0.9)
1.1  
(0.9, 1.4)
22.9  
(22.3, 23.5)
10.6  
(8.9, 12.3)
Wild 6.086  
(5.974, 6.199)
6. H460 LC 20.0  
(19.1, 21.0)
17.8  
(17.1, 18.5)
97.0  
(82.7, 111.2)
1595.7  
(1491, 1701)
Wild 10.089  
(9.565, 10.614)
7. H522 A 0.2  
(0.2, 0.2)
0.0  
(0.0, 0.0)
44.9  
(40.2, 49.6)
0.9  
(0.6, 1.2)
Wild 12.679  
(12.094, 13.264)
8. H647 AS 2.8  
(2.5, 3.1)
9.8  
(8.1, 11.5)
63.6  
(60.1, 67.1)
1226.2  
(976.5, 1476.7)
Wild 12.474  
(12.054, 12.895)
9. H820 A 1.9  
(1.9, 2.0)
17.9  
(14.2, 21.7)
13.5  
(12.3, 14.7)
48.5  
(44.5, 52.4)
del 746–749, 
T790M 
c-Met 
amplification
4.717  
(4.694, 4.738)
10. H838 AS 0.0  
(0.0, 0.1)
0.9  
(0.7, 1.2)
54.6  
(52.0, 57.2)
704.3  
(679.2, 729.5)
Wild 12.372  
(12.104, 12.640)
11. H1155 LC 380.0  
(372.2, 387.8)
0.4  
(0.3, 0.6)
7.3  
(6.9, 7.6)
2.4  
(2.2, 2.5)
Wild 7.043  
(6.925, 7.160)
12. H1299 LC 935.8  
(903.3, 968.3)
1.0  
(0.8, 1.1)
20.8  
(20.2, 21.5)
13.2  
(11.8, 14.6)
Wild 6.162  
(6.003, 6.320)
13. H3255 A 0.5  
(0.4, 0.6)
1.9  
(1.8, 2.0)
6.7  
(6.1, 7.3)
13.6  
(12.4, 14.8)
L858R 0.0042  
(0.004, 0.004)
14. HCC827 A 0.4  
(0.2, 0.6)
4.0  
(3.3, 4.6)
18.0  
(16.8, 19.3)
304.4  
(293.8, 315.0)
del 746–750 0.0025  
(0.002, 0.003)
15. PC-9 A 0.2  
(0.2, 0.1)
4.0  
(3.2, 4.7)
22.5  
(20.4, 24.6)
3019.3  
(2830.7, 3208.0)
del 746–750 0.0235 (0.024, 
0.024)
Cell lines with high levels of induced Pgp (N = 2)
16. H23-A0.1 A 257.8  
(218.2, 297.4)
0.3  
(0.2, 0.5)
1.1  
(0.9, 1.4)
0.3  
(0.2, 0.3)
Wild 12.605  
(12.296, 12.915)
17. H23-A0.3 A 522.8  
(495.9, 549.6)
0.2  
(0.1, 0.4)
1.4  
(1.2, 1.6)
0.4  
(0.3,0.5)
Wild 12.499  
(12.211, 12.786)
A, adenocarcinoma; AS, adenosquamous-cell carcinoma; S, squamous-cell carcinoma; BAC, bronchioloalveolar cell carcinoma; LC, large-cell carcinoma; ABCT, adenosine-5' 
triphosphate-binding cassette transporter; MDR1, multidrug resistance 1 gene; Pgp, P-glycoprotein, the protein product of the MDR1 gene; BCRP, breast cancer resistance protein; 
MRP1, multidrug resistance-associated protein 1; MRP2, multidrug resistance-associated protein 2. 
a Cell lines 1–15 were derived from the tumors of previously untreated patients, whereas cell lines 16, H23-A0.1 and 17, H23-A0.3 were derived from long-term incubation of 
NCI-H23 (H23) cells in medium containing doxorubicin at 0.1 and 0.3 μM, respectively.
b The results of three independently performed qRT-PCR experiments were quantitated and expressed as mean values (see text). Numbers in parentheses are 95% confidence 
intervals.
c The IC
50
 values were defined as the concentrations of gefitinib that produced 50% reduction in control absorbance. The results reported as IC
50
 are the means of three indepen-
dent assays performed in quadruplicate wells. Numbers in parentheses are 95% confidence intervals.
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effects of drug combinations. The study design is shown in 
Supplementary Figure 1 and Supplementary Appendix and, 
Supplemental Digital Content 1 and 2, http://links.lww.com/
JTO/A287 and http://links.lww.com/JTO/A288. The cytotoxic 
effects of five single agents, gefitinib, gemcitabine, paclitaxel, 
docetaxel, and vinorelbine, and the four combinations of gefi-
tinib with other drugs were tested in all 17 cell lines.
Combination Effect Identification and Data 
Analysis
Cell survival was determined using an (3-[4,5-dimethyl-
2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) colo-
rimetric assay. The percentage of control absorbance 
represented the surviving fraction of cells, and the IC
50
 values 
were defined as the concentrations of drug that produced a 
50% reduction in control absorbance. The combination index 
(CI) at the 50%-effect level was defined as the sum of the rela-
tive doses of each individual drug yielding an isoeffect (50% 
in this study) on cell killing when added together, and was 
used to represent the combination effects of test drugs. CI was 
calculated as (dose of gefitinib/IC
50
 of gefitinib) + (dose of 
drug X/IC
50
 of drug X) for each drug combination.
The mean values of the survival fractions were used to 
generate a set of CI values (data points), construct the isobole 
for a particular cell line and drug combination, and construct 
the log-dose-versus-response curves and the dose-versus-log-
response curves. The mean combination index value (mCI) 
for this set was reported as the summary measure for each cell 
line. Upper and lower bounds of 1.05 and 0.95 were selected 
as being of interest (based on a preset “null” interval of 0.95–
1.05), so that mCI values more than 1.05 and less than 0.95 
are interpreted as suggestive of antagonism and synergism, 
respectively. The mCIs for gefitinib/gemcitabine (GGe), gefi-
tinib/paclitaxel (GP), gefitinib/docetaxel (GD), and gefitinib/
vinorelbine (GN) combinations were designated mCIGGe, 
mCIGP, mCIGD, and mCIGN, respectively.
Sign tests were performed on each set of CI values to 
formally evaluate whether antagonism or synergism was evi-
dent for a particular cell line and drug combination at the 
50%-effect level. In addition, Wilcoxon signed rank tests were 
computed to evaluate whether significant differences in the 
cell-line means occurred compared with a null hypothesis of 
a mCI of one, and to analyze the differences between the drug 
interactions of the tested regimens. The Spearman rank cor-
relation was used to analyze the correlations between the IC
50
 
values of the drugs and the mCIs of the gefitinib-containing 
regimens. All tests were two sided, and p value less than 0.05 
were considered significant.
Dose-Versus-Log-Response Curve Analysis
Stewart et al.28,29 have hypothesized that the dose-ver-
sus-log-response curve (DRC) might offer insight into the 
nature of drug–cell interaction and provide information on 
how cancer cells become resistant or sensitive after treat-
ment. To elucidate the nature of the drug interaction in the 
tested cell lines, we plotted and examined the curve and the 
change produced by gefitinib on the shape of the curve, for 
each AMTA in each cell line. DRCs demonstrate an initial 
shoulder for active resistance (because of excess of a resis-
tance factor such as efflux pump or a repair process), a ter-
minal plateau for saturable passive resistance (because of 
deficiency or saturation of a factor required for cell killing), 
and a change in the slope of the curve for nonsaturable pas-
sive resistance (because of change or alteration of a target, 
transport system, etc.), and combinations of these mecha-
nisms may exist in a given tumor or cell line. In this study, we 
plotted DRCs of the gefitinib-drug combination, examined 
the DRC shape and the effect of gefitinib on the shape of the 
curve of chemotherapeutic drug, and tried to determine the 
nature of the drug interaction.
Although there is no clinically relevant, highly selective 
Pgp blocker to elucidate the patterns of DRC shape change 
of drug interactions, we used reserpine as a Pgp blocker to 
test the in vitro combination effects of reserpine plus pacli-
taxel or docetaxel in four cell lines H23, H23-A0.1, H1299, 
and H125. Of these cell lines, H23 and H125 showed no 
detectable Pgp, H23-A.01 had a high level of induced Pgp, 
and H1299 showed a high level of de novo Pgp (Table 1). 
The isobolograms and DRCs of the two-drug combinations 
were analyzed and compared with the results of gefitinib plus 
AMTA combinations.
RESULTS
In Vitro Expression of Pgp, BCRP, MRP1, and 
MRP2
The relative expression levels of Pgp, BCRP, MRP1, 
and MRP2 were determined using qRT-PCR analyses, and the 
results are summarized in Table 1 and Figure 1. Two cell lines 
H1155 and H1299, had the highest levels of de novo Pgp, and 
as anticipated, the doxorubicin-selected subclones H23-A0.1 
and H23-A0.3 also showed high levels of Pgp. The other cell 
lines expressed very low levels of Pgp. Of these, H460 and 
H647 simultaneously expressed higher levels of other ABCTs. 
Single-Agent Sensitivities In Vitro
The results of drug testing are summarized in Table 1 
(gefitinib) and Supplementary Table 1 (chemotherapeutics). 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A288). Three cell lines harboring sensitizing EGFR muta-
tions, H3255, HCC827, and PC-9 showed supersensitivity to 
gefitinib. H820, which had gefitinib-sensitizing and -resistant 
EGFR mutations and c-Met amplification, showed sensitivity 
similar to that of EGFR wild-type cells. Among the 15 cell 
lines, the IC
50
 values of the three AMTAs were tightly cor-
related (R = 0.879 to.964, all p < 0.001). Otherwise, sensitiv-
ity to the test agents was not closely correlated. Compared 
with NCI-H23, H23-A0.1 and H23-A0.3 expressed higher 
levels of Pgp but similar levels of BCRP and MRPs. H23-
A0.1 and H23-A0.3 demonstrated a modest increase in IC
50
 
with gefitinib and gemcitabine, but a 30- to 80-fold and 40- to 
120-fold increase of IC
50
 with AMTAs, respectively (Table 1 
and Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A288). 
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More Synergistic Gefitinib-AMTA Interactions 
in Cells Without Than With Sensitizing EGFR 
Mutations
In 15 cell lines, statistically significant synergism was 
observed for the GD (mCIGD = 0.870, 95% confidence inter-
val 0.78–0.96, p = 0.017) and GN (mCIgn = 0.899, 95% CI 
0.826–0.98, p = 0.041) combinations. The GP combination 
was marginally synergistic (mCIgp = 0.911, 95% CI 0.83–
0.90, p = 0.078). In contrast, the GGe combination seemed to 
be additive (mCIgge = 1.027, 95% CI 0.95–1.11, p = 0.683) 
(Table 2 and Fig. 2A). We further noticed that the three cell 
lines harboring sensitizing EGFR mutations showed only 
additivism (H3255) or even antagonism (HCC827 and PC-9) 
when gefitinib was combined with these cytotoxic agents. 
The group results of the three gefitinib/AMTA combinations 
in the other 12 cell lines clearly showed synergism (Table 2 
and Fig. 2B). Differences among different gefitinib/AMTA 
combinations were not statistically significant, except that 
GD showed more synergism than did GP in the entire group 
of 15 cell lines or in the 12 nonsensitizing-EGFR mutants 
(p = 0.008; Fig. 2C). 
Inhibition of Pgp-Associated Efflux and 
Decreased AMTA Resistance by Gefitinib in 
Pgp-Overexpressing Cells
H23-A0.1 and H23-A0.3 demonstrated a remarkable 
synergism of similar degree with various gefitinib/AMTA 
combinations (mCI = 0.484–0.552). This synergism was not 
seen in NCI-H23, or with the GGe combination in these lines 
(Fig. 3A).
We further examined the effect of gefitinib on ABCT 
efflux function in these cells. As shown in Figure 3B, the fluo-
rescence of rhodamine 6G was equal throughout in H23 cells 
(left top). In contrast, the fluorescence was barely detectable 
in H23-A0.1 and H23-A0.3 cells (left panel, middle and bot-
tom). Adding reserpine restored intracellular accumulation of 
fluorescence (right panel); with exposure to increasing con-
centrations of gefitinib (0.32–10 μM), the intracellular fluo-
rescence increased in H23-A0.1 and H23-A0.3 cells, but not 
in NCI-H23 cells. These results indicate that gefitinib can act 
as a Pgp inhibitor to increase intracellular drug accumulation 
and thus decrease AMTA resistance in Pgp-overexpressing 
cells.
We thought that Pgp expression might be a predictor 
for gefitinib/AMTA synergism. In this panel of cell lines, 
only H1155 and H1299 expressed high levels of de novo Pgp 
(Table 1 and Fig. 1) and showed obvious synergism for all 
gefitinib/AMTA combinations (mCI = 0.609–0.859) (Table 2). 
By contrast, gefitinib had little influence on the effects of 
AMTAs in H460 and H647, which expressed high levels of 
BCRP and MRPs but almost undetectable Pgp.
Figure 3C shows examples of isobolograms of different 
gefitinib/AMTA combinations in three individual cell lines. 
Marked GN and GP synergism were seen in gefitinib-insen-
sitive H1155 (a) and H226 (b), respectively, but a striking GD 
antagonism was observed in gefitinib-sensitive PC-9 cells (c). 
The isoboles shown in Figure 3C, a and b, demonstrate that 
gefitinib at a concentration as low as 5% of the IC
50
 (~0.45 
μM) could decrease the IC
50
 of AMTAs by approximately 50% 
(shaded areas).
Combined Effects of Various Gefitinib-AMTA 
Combinations
We observed close correlations between the mean com-
bination index values of three gefitinib/AMTA combinations 
(all p < 0.001), but the mCI value of GGe was not significantly 
correlated with that of any gefitinib/AMTA combination 
(p values = 0.243–0.428). These findings suggested that a 
similar mechanism might be involved in the three EGFR-TKI/
AMTA interactions. Interestingly, four cell lines (H125, H226, 
H358, and H820) that showed gefitinib/AMTA synergism 
demonstrated almost undetectable levels of Pgp (Tables 1 and 2, 
Fig. 1). To identify the possible mechanism underlying this 
synergism, we examined changes in the DRCs of AMTAs with 
various concentrations of gefitinib. Representative examples are 
FIGURE 1. The expression levels of four multiple-drug 
resistance-associated transcripts (MDR1, BCRP, MRP1, and 
MRP2) in the 17 tested cell lines were determined by real-
time quantitative reverse transcription polymerase chain reac-
tion. In a particular cell line, the gene level was normalized 
to glyceraldehyde-3-phosphate dehydrogenase (ΔCt). The 
relative gene expression level was calculated using the equa-
tion 2−ΔΔCt as the value relative to that of the calibrator sample 
(NCI-H23). Mean values and 95% confidence intervals (error 
bars) generated from three independent assays are shown.
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TABLE 2. Results of Drug Combinations
Cell Line
Mean Combination Index (mCI)
Gefitinib Plus 
Gemcitabine 
(mCIGGe)
Gefitinib Plus 
Paclitaxel 
(mCIGP) 
Gefitinib Plus 
Docetaxel 
(mCIGD)
Gefitinib Plus 
Vinorelbine 
(mCIGN)
1. H23 0.999 (0.974, 1.025)  
Add [8]
0.965 (0.926, 1.004) 
Add [9]
0.904 (0.852, 0.956) 
Syn [9]
0.987 (0.970, 1.003) 
Add [9]
2. H125 1.000 (0.901, 1.100) 
Add [8]
0.760 (0.644, 0.876) 
Syn [12]
0.813 (0.706, 0.920) 
Syn [9]
0.645 (0.490, 0.800) 
Syn [11]
3. H226 1.098 (1.018, 1.178) 
Ant [8]
0.696 (0.431, 0.784) 
Syn [9]
0.619 (0.506, 0.733) 
Syn [9]
0.732 (0.680, 0.783) 
Syn [8]
4. H322 1.053 (0.958, 1.148) 
Add [5]
1.021 (0.969, 1.072) 
Add [7]
1.004 (0.964, 1.043) 
Add [7]
1.065 (0.994, 1.135) 
Add [7]
5. H358 0.938 (0.863, 1.014) 
Add [9]
0.776 (0.673, 0.879)
Syn [11]
0.728 (0.627, 0.829) 
Syn [7]
0.739 (0.633, 0.845) 
Syn [8]
6. H460 0.975 (0.908, 1.041)
Add [9]
0.996 (0.938, 1.055) 
Add [8]
0.990 (0.926, 1.055) 
Add [8]
0.892 (0.792, 0.992) 
Add [9]
7. H522 0.996 (0.945, 1.047)
Add [10]
1.007 (0.927, 1.086) 
Add [9]
0.919 (0.845, 0.993) 
Add [9]
0.957 (0.854, 1.059) 
Add [10]
8. H647 0.831 (0.771, 0.890)
Syn [7]
0.976 (0.902, 1.050) 
Add [9]
0.908 (0.839, 0.977) 
Add [10]
0.915 (0.838, 0.993) 
Add [9]
9. H820 0.687 (0.582, 0.791)
Syn [8]
0.718 (0.561, 0.875) 
Syn [7]
0.585 (0.427, 0.744) 
Syn [7]
0.795 (0.736, 0.854) 
Syn [10]
10. H838 1.255 (1.067, 1.443) 
Ant [9]
1.020 (1.001, 1.039) 
Add [10]
0.993 (0.968, 1.019) 
Add [9]
1.022 (0.983, 1.060) 
Add [10]
11. H1155 1.261 (1.094, 1.427) 
Ant [10]
0.669 (0.525, 0.814) 
Syn [9]
0.609 (0.459, 0.759) 
Syn [7]
0.633 (0.472, 0.794) 
Syn [9]
12. H1299 0.989 (0.879, 1.098) 
Add [6]
0.828 (0.733, 0.922) 
Syn [10]
0.773 (0.648, 0.897) 
Syn [7]
0.859 (0.758, 0.960) 
Syn [9]
13. H3255 0.953 (0.921, 0.986) 
Add [10]
0.994 (0.951, 1.036) 
Add [7]
0.930 (0.821, 1.039) 
Add [6]
0.971 (0.901, 1.042) 
Add [7]
14. HCC827 1.151 (1.058, 1.244) 
Ant [7]
1.091 (1.036, 1.146) 
Ant [6]
1.141 (1.029, 1.253) 
Ant [7]
1.135 (1.037, 1.232) 
Ant [7]
15. PC-9 1.227 (1.080, 1.374) 
Ant [8]
1.145 (1.060, 1.229) 
Ant [9]
1.129 (1.056, 1.203) 
Ant [8]
1.140 (1.056, 1.224) 
Ant [10]
Cell lines with high levels of induced Pgp (N = 2)
16. H23-A0.1 0.997 (0.938, 1.057) 
Add [10]
0.484 (0.299, 0.670) 
Syn [9]
0.486 (0.264, 0.708) 
Syn [7]
0.501 (0.334, 0.668) 
Syn [8]
17. H23-A0.3 1.058 (1.017, 1.099) 
Ant [9]
0.493 (0.321, 0.665) 
Syn [9]
0.525 (0.290, 0.760) 
Syn [7]
0.552 (0.374, 0.730) 
Syn [9]
Group results of the 15 previously untreated cell lines (Nos. 1–15)
Mean CIa 1.027 (0.948, 1.107) 0.911 (0.833, 0.989) 0.870 (0.780, 0.960) 0.899 (0.816, 0.982)
p valuea 0.683 0.078 0.017 0.041
Resulta Additivism Additivism Synergism Synergism
Group results of 12 cell lines with no sensitizing EGFR mutation (Nos. 1–12)b
Mean CIa 1.007 (0.917, 1.096) 0.869 (0.790, 0.949) 0.820 (0.732, 0.909) 0.853 (0.771, 0.935)
p valuea 0.859 0.019 0.003 0.010
Resulta Additivism Synergism Synergism Synergism
mCI, the mean value of the combination index at the 50%-effect level (see text); GGe, gefitinib + gemcitabine; GP, gefitinib + paclitaxel; GD, gefitinib + docetaxel; GN, 
gefitinib + vinorelbine; CI, combination index; EGFR, epidermal growth factor receptor. Signed tests were applied to formally evaluate whether antagonism (Ant) or synergism 
(Syn) was evident for a particular cell line and drug combination. Otherwise, the interaction was additivism (Add). Numbers in parentheses, 95% confidence intervals; numbers in 
brackets, number of data points generated from the survival fractions of three independently performed experiments (see text).
aWilcoxon signed rank tests were performed to evaluate whether group means were significantly different compared with the null hypothesis of a CI of one.
bCell lines with sensitizing EGFR mutations (H3255, HCC827, and PC-9) were excluded. Numbers in parentheses are 95% confidence intervals.
shown in Figure 4. The basic shape of the DRCs comprised 
an initial shoulder and terminal plateau, contributed by active 
and saturable passive resistance mechanisms, respectively. We 
found that in cell lines showing additive interactions, the shape 
of DRCs barely changed (Fig. 4A). In contrast, in cell lines 
with synergistic gefitinib/AMTA interactions, three major 
types of DRC changes were observed1: a shortened shoulder 
in cells with acquired Pgp-overexpression (Fig. 4B)2; a down-
ward shift of the terminal plateau in cells with almost unde-
tectable Pgp (Fig.4C); and3 both a shortened shoulder and a 
lower terminal plateau in cells with (Fig. 4D and E) or without 
(Fig. 4F) de novo Pgp-overexpression. With shortening the 
1224 Copyright © 2012 by the International Association for the Study of Lung Cancer
Tsai et al. Journal of Thoracic Oncology  •  Volume 7, Number 8, August 2012
FIGURE 2. A, Mean combination index (mCI) distribution of gefitinib/gemcitabine, gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/
vinorelbine of the 15 cell lines derived from tumors of previously untreated patients (T). The group results are shown and expressed as mCI val-
ues (see Materials and Methods) with 95% confidence intervals (error bars). Of these 15 cell lines, three had (M) and 12 had no (W) sensitizing 
epidermal growth factor receptor mutations. B, The subgroup results of various gefitinib-drug combinations by sensitizing-epidermal growth 
factor receptor mutation status are shown and expressed as mCIs with 95% confidence intervals (error bars). C, Statistical analyses of the group 
difference between regimens were done by the Wilcoxon signed rank test. The group mCIs for gefitinib/gemcitabine, gefitinib/paclitaxel, gefi-
tinib/docetaxel, and gefitinib/vinorelbine combinations are designated mCIGGE, mCIGP, mCIGD, and mCIGN, respectively. N.S., no statistically 
significant difference. (Shaded area in A and B: additivism based on a null interval of 0.95–1.05.) mCI, mean combination index.
FIGURE 3. A, The combination effects of gefitinib plus gemcitabine, paclitaxel, docetaxel, or vinorelbine in NCI-H23 and its Pgp-
overexpressing subclones H23-A0.1 and H23-A0.3. The mean combination index values and 95% confidence intervals (error bars) 
generated from the three independent assays performed in quadruplicate are plotted. Signed tests were applied to evaluate whether 
antagonism (Ant) or synergism (S) was evident for a particular cell line and drug combination. Otherwise, the interaction was additiv-
ism (Ad). The differences in drug interactions between cell lines were analyzed using the Wilcoxon signed rank test. Numbers in 
brackets are the number of data points. (Shaded area: additivity based on a null interval of 0.95–1.05.) B, Inhibition of the rhodamine 
6G fluorescence-effluxing capacity of adenosine-5' triphosphate-binding cassette transporters by gefitinib at 0.3 to 10 μM. Rhodamine 
6G was used as the fluorescence probe to imitate anticancer agents. Reserpine, a P-glycoprotein inhibitor, was used as a positive 
control. C, The isobolograms of gefitinib/vinorelbine in H1155 cells (a), gefitinib/paclitaxel in H226 cells (b), and gefitinib/vinorelbine 
in HCC827 cells (c). Data points above the dash diagonal line representing the additive effect in the isobole suggest antagonism, and 
those below the diagonal suggest synergism. (Shaded area: the area where the concentration of gefitinib ≤ 5% of IC50)
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shoulder and/or downward shifting the terminal portion of the 
DRC, the slope of the DRCs increased and the curves shifted 
leftward. All the changes occurred in a gefitinib-dose–depen-
dent fashion and, more importantly, at clinically achievable 
concentrations (≤1 μM).30,31 These findings suggest that the 
resistance-reducing effect of gefitinib might not be restricted 
to a Pgp blockage that manifested as a shortened shoulder of 
the DRC. Moreover, the change in the terminal plateau, dem-
onstrating that every molecule of AMTA taken up was more 
effective with increasing concentrations of gefitinib, further 
indicated that gefitinib might contribute to the gefitinib/
AMTA synergism by reducing saturable passive resistance in 
cells, regardless of their Pgp status. 
The in vitro combination effects of reserpine plus pacli-
taxel or docetaxel in H23, H23-A0.1, H1299, and H125 were 
tested. Results are shown in the Supplementary Appendix 
(Supplemental Digital Content 2, http://links.lww.com/JTO/
A288) and Supplemental Figs. 2–4 (Supplemental Digital 
Content 3–5, http://links.lww.com/JTO/A312, http://links.lww.
com/JTO/A313, and http://links.lww.com/JTO/A314). This 
small-scale study showed results of drug interactions and pat-
terns of DRC shape change that were very similar to those of 
the gefitinib/AMTA combinations.
DISCUSSION
In this study, we showed that the effects of combined gefi-
tinib with AMTAs were synergism. In contrast, the combination 
effect of gefitinib and gemcitabine was additivism. The close 
correlations between the CI values of different gefitinib/AMTA 
combinations indicated that the synergistic interactions involved 
similar mechanisms. In the induced Pgp-overexpressing NCI-
H23 subclones, we demonstrated that gefitinib had no effect on 
gemcitabine cytotoxic activity, but strikingly enhanced AMTA 
sensitivity by blocking Pgp-associated efflux, an active resis-
tance mechanism. We also observed marked gefitinib/AMTA 
synergism in two de novo Pgp-overexpressing lines, but mostly 
additivism in cell lines that expressed high levels of MDR-
associated proteins other than Pgp.
Interestingly, gefitinib could also enhance de novo AMTA 
sensitivities in Pgp-undetectable cell lines. Based on the find-
ings of DRC analysis, we speculate that gefitinib, in addition to 
reducing Pgp-associated active resistance in Pgp-overexpressing 
cells, might also reduce some other form of active resistance 
in Pgp-undetectable cells and reduce saturable passive AMTA 
resistance in cells with and without Pgp-overexpression (Fig. 4). 
These effects of gefitinib were dose-dependent and at clinically 
achievable concentrations (~1 μM).30,31
The decrease of non–Pgp-associated active resistance 
by gefitinib was unlikely to be associated with modification 
FIGURE 4.  The effects of gefitinib on the dose-versus-log-response curves of paclitaxel, docetaxel, or vinorelbine in six NSCLC 
cell lines. A, H838 cells, expressing almost undetectable levels of Pgp, had an additive gefitinib/paclitaxel interaction. B, H23-
A0.1 cells, with induced P-glycoprotein (Pgp)-overexpression, had a synergistic gefitinib/docetaxel interaction. C, H125 cells, 
exhibiting nearly undetectable Pgp levels, showed a synergistic gefitinib/vinorelbine interaction. D, H1299 and E, H1155 cells, 
both expressing de novo Pgp, showed a synergistic gefitinib/paclitaxel and gefitinib/vinorelbine interaction, respectively. F, 
H226 cells, with nearly undetectable Pgp levels, showed a synergistic gefitinib/docetaxel interaction (see Results). Mean survival 
fraction and 95% confidence intervals (error bars) generated from three independent assays performed in quadruplicate are 
shown. The mCIs for gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/vinorelbine combinations are designated mCIGP, 
mCIGD, and mCIGN, respectively. mCI, mean combination index.
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of other ABCTs tested in this study. For example, in H226, 
which expressed undetectable ABCTs including Pgp, gefi-
tinib reduced the shoulder part of the DRC of vinorelbine. 
The downward and leftward shift of the curve reflected an 
increase in vinorelbine cytotoxicity (Fig. 4F). These findings 
suggested that gefitinib, in addition to Pgp inhibition, reduces 
primary and acquired AMTA resistance in NSCLC cells. Used 
as an AMTA-potentiating agent, gefitinib is better than reser-
pine because of its clinical relevance. Moreover, gefitinib, in 
vitro, might show a wider spectrum than reserpine, enhancing 
AMTA cytotoxicity in Pgp-undetectable cells, e.g., paclitaxel 
in H125—data are showed in the Supplementary Appendix 
(Supplemental Digital Content 2, http://links.lww.com/JTO/
A288) and Supplemental Figs. 2–4 (Supplemental Digital 
Content 3–5, http://links.lww.com/JTO/A312, http://links.
lww.com/JTO/A313, and http://links.lww.com/JTO/A314). 
The non–Pgp-associated and gefitinib-sensitive AMTA resis-
tance mechanisms deserve to be further explored.
We further examined the differences between the effects 
of combinations on cells with and without sensitizing EGFR 
mutations to test the role of sensitizing EGFR mutation in com-
bination drug effect. Unexpectedly, synergism seemed more 
likely to occur in cells without sensitizing mutations. Among 
the panel of 15 cell lines, only two (HCC827 and PC-9) showed 
antagonism to the combinations, both cell lines had sensitiz-
ing mutations. The other sensitizing EGFR mutant, H3255, 
showed additivism at best. In contrast, the drug combinations 
had a synergistic effect on the gefitinib-insensitive mutant 
cell line H820. The explanation for nonsynergistic gefitinib/
AMTA interactions in cell lines with sensitizing EGFR muta-
tion is unclear and deserves further investigation. However, it 
is reasonable to speculate that the gefitinib hypersensitivity 
and its associated oncogenic shock in these cells might lead to 
a spectrum of chemorefractoriness and antagonism when con-
comitantly treated with EGFR-TKI and AMTAs.
In the TRIBUTE study,7 EGFR mutations seemed to 
predict a better response in patients receiving frontline che-
motherapy with erlotinib than without erlotinib (53% versus 
21%). However, a better response (~70%) is predicted in this 
group of patients when they received a single EGFR-TKI as 
frontline therapy,32–34 suggesting a possible negative interaction 
between EGFR-TKI and platinum-based chemotherapy. In 
fact, we recently demonstrated that the combined gefitinib/cis-
platin was obviously antagonistic9 in this panel of cell lines. In 
that study, we also demonstrated that three-drug combinations 
(paclitaxel/cisplatin/gefitinib) were no better than two-drug 
combinations (paclitaxel/cisplatin or paclitaxel/gefitinib), sug-
gesting that EGFR-TKI/platinum antagonism could be a possi-
ble reason for the failure of those trials.2–5 Our theory is further 
supported by the results of recently reported clinical studies, 
which demonstrated that single erlotinib or erlotinib plus pacli-
taxel/carboplatin yielded similar outcomes in patients who had 
tumors harboring sensitizing EGFR mutations.8,10 
Previous preclinical studies suggested that cell-cycle–
specific antagonism occurs when EGFR-TKI is administered 
before or concomitantly with chemotherapeutics that act beyond 
the G1 phase.6 However, this is unlikely, as seen in this and 
our previous studies.9 We have shown that gefitinib given con-
comitantly with various chemotherapeutics that act beyond G1 
phase had different interactions: with cisplatin, gemcitabine or 
AMTAs is antagonism, additivism or synergism, respectively. 
The results of interactions of EGFRTKI-chemotherapeutics 
are cell-line, drug, and administration-schedule9 dependent.
Although there was no chemotherapy alone arm in the 
study of Hirsch et al.,10 the results with intercalated therapy 
in EGFR wild-type patients (response rate 22.7% and dis-
ease control rate 68.2%) were similar to those reported with 
chemotherapy alone.4,5 Therefore, that trial does not support 
use of intercalated EGFR-TKI with platinum-based chemo-
therapy in the frontline setting in EGFR wild-type patients. 
The explanations for the failure could be deprivation of posi-
tive interactions between EGFR-TKI and paclitaxel simply 
because of administration separation, and a possible antago-
nistic interaction between erlotinib and platinum because of 
inadequate administration interval.9
Our findings have several clinical implications. First, 
we consider EGFR-TKIs at clinically achievable doses to be 
useful agents for reducing acquired AMTA resistance. Second, 
as demonstrated, EGFR-TKIs may serve as a good adjunct to 
primary chemotherapy for some types of cancers including 
NSCLC (e.g., adding AMTA on EGFR-TKI in NSCLC patients 
who have disease progression after initial TKI response). 
Third, all chemotherapeutic agents do not have equal effects 
in combination with EGFR-TKI in NSCLC. AMTAs are a bet-
ter choice than gemcitabine or cisplatin.9 In fact, our clinical 
observation was in accordance with the present in vitro study.35 
In conclusion, our preclinical study demonstrated 
that combining gefitinib with AMTAs showed synergism 
in NSCLC cells harboring no sensitizing EGFR mutations. 
Gefitinib could enhance AMTA effects through mechanisms 
not restricted to Pgp blockage.
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